Global dental implant leader Dentium is set to strengthen its position in the Chinese market with its latest brand, bright Implant. The company announced on October 8th that it received approval for the product from China's National Medical Products Administration (NMPA) in August 2025.

China represents one of the world's most significant high-potential dental markets, with particularly remarkable growth in the implant sector. Dentium has already established a solid foothold as a leading Korean provider in the region. Leveraging its Shanghai Fengxian factory, operational since 2024, the company has built a diverse portfolio. This ranges from cost-effective solutions to the locally-optimized SuperLine 2 implant and now includes the newly approved premium bright Implant. This comprehensive lineup allows Dentium to cater to all market segments, from entry-level to premium, creating a strong foundation to expand its sales and reinforce its influence across China.

The bright Implant system is the culmination of over two decades of Dentium's accumulated R&D expertise and clinical data. It is engineered for exceptional efficiency and long-term stability throughout the surgical and prosthetic phases. A key feature is its versatility, allowing for placement in challenging cases with limited bone width or height, often without the need for additional augmentation procedures. The system is fully compatible with state-of-the-art digital workflows, integrating seamlessly with intraoral scanners, dental CT, and CAD/CAM systems. This enables the fabrication of highly aesthetic and precise prosthetics, ultimately providing patients with faster, more comfortable treatment and offering clinicians a more efficient clinical environment.

Since its initial launch in South Korea in 2019, the bright Implant has earned a strong reputation among clinicians and patients for its reliability and ease of use. The NMPA approval is a significant milestone that not only validates its product competitiveness on a global scale but is also poised to significantly enhance Dentium's brand equity and influence within the vital Chinese market.

A representative from Dentium stated, "The NMPA approval for bright Implant is a pivotal moment that will solidify our competitive advantage in China and further establish Dentium as a leading global brand. Moving forward, we will continue to leverage our advanced technology and unwavering commitment to quality to provide clinicians with highly efficient treatment solutions and patients with safer, more comfortable clinical experiences."